|
業務類別
|
-- |
|
業務概覽
|
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US. |
| 公司地址
| 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000 |
| 電話號碼
| +61 396604900 |
| 傳真號碼
| +61 396604909 |
| 公司網頁
| https://www.clinuvel.com |
| 員工數量
| 16 |
| Dr. Philippe J. Wolgen, M.B.A.,M.D. |
Director, Managing Director and Chief Executive Officer |
-- |
28/08/2025 |
|
|
| Ms. Susan Smith |
Director |
28/08/2025 |
| Mr. Matthew Pringle |
Director |
28/08/2025 |
| Professor Jeffrey Rosenfeld |
Chairman of the Board |
28/08/2025 |
| Dr. Karen Agersborg |
Director |
28/08/2025 |
| Dr. Philippe J. Wolgen, M.B.A.,M.D. |
Director, Managing Director and Chief Executive Officer |
28/08/2025 |
| Mr. Guy Van Dievoet |
Director |
28/08/2025 |
| Ms. Pearl Grimes |
Director |
28/08/2025 |
|
|
|
|
